The collaboration focuses on intravenously administered treatments targeting the tau gene, associated with Alzheimer’s disease and other tauopathies. Credit: Milad Fakurian on Unsplash.

Sangamo Therapeutics has signed a global licence agreement with Roche Group member Genentech for the development of genomic medicines to treat neurodegenerative diseases.

The collaboration focuses on intravenously administered treatments targeting the tau gene, associated with Alzheimer’s disease and other tauopathies, and a second undisclosed neurology target.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Sangamo has granted Genentech an exclusive licence for its zinc finger repressors for the tau gene and the neurology target.

Sangamo’s neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, will be exclusively licensed to Genentech for these targets.

STAC-BBB has shown significant blood-brain barrier penetration and brain transduction in nonhuman primates.

Sangamo is tasked with concluding a technology transfer and certain preclinical works, while Genentech will handle the complete clinical development, regulatory works, manufacture and commercialisation of the assets globally.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sangamo is entitled to receive $50m from Genentech in near-term upfront license fees and milestone payments, and could receive $1.9bn in development and commercial milestones across multiple potential products, as well as tiered royalties on net product sales.

The company is also in discussions with other collaboration partners regarding its STAC-BBB capsid delivery platform, epigenetic regulation capabilities and other assets, including treatments for Fabry disease.

Sangamo Therapeutics CEO Sandy Macrae stated: “Sangamo has been pioneering the field of genomic medicine for years to address devastating neurodegenerative diseases with limited current treatment options.

“We strongly believe in the power of our zinc finger technology to regulate the expression of key genes involved in disease. The recent discovery of our industry-leading intravenously delivered AAV capsid, STAC-BBB, has the potential to address longstanding challenges in delivering therapeutics to the central nervous system.”

In January 2024, Genentech partnered with GenEdit to use the latter company’s non-viral delivery platform for gene editing therapies.